cisplatin + gemcitabine + itraconazole

Cisplatin + gemcitabine + itraconazole is an investigational combination chemotherapy regimen evaluated for the treatment of metastatic squamous non-small cell lung cancer (NSCLC). This regimen combines two standard cytotoxic agents—cisplatin, a platinum-based DNA crosslinking agent, and gemcitabine, a nucleoside analog—with SUBA™-itraconazole. While traditionally used as an antifungal, itraconazole is repurposed here for its antiangiogenic properties, specifically its ability to inhibit VEGF- and bFGF-mediated pathways, thereby suppressing endothelial cell proliferation and tube formation. The SUBA™ (supersaturated bioavailability) formulation of itraconazole is used to enhance oral absorption. A Phase II trial led by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins was initiated to assess this triplet's efficacy but was terminated early due to low patient accrual.

Brand names

TolsuraLozanoc

Other names

SUBA-itraconazole with Cisplatin/Gemcitabine